CA3229020A1 - Treatment of cardiovascular disease - Google Patents
Treatment of cardiovascular disease Download PDFInfo
- Publication number
- CA3229020A1 CA3229020A1 CA3229020A CA3229020A CA3229020A1 CA 3229020 A1 CA3229020 A1 CA 3229020A1 CA 3229020 A CA3229020 A CA 3229020A CA 3229020 A CA3229020 A CA 3229020A CA 3229020 A1 CA3229020 A1 CA 3229020A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- acid molecule
- seq
- nucleotide sequence
- sense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2113104.0 | 2021-09-14 | ||
| GBGB2113104.0A GB202113104D0 (en) | 2021-09-14 | 2021-09-14 | Antagonist of pcsk9 |
| GB2207239.1 | 2022-05-18 | ||
| GBGB2207239.1A GB202207239D0 (en) | 2022-05-18 | 2022-05-18 | Treatment of cardiovascular disease 2 |
| PCT/EP2022/075355 WO2023041508A2 (en) | 2021-09-14 | 2022-09-13 | Treatment of cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3229020A1 true CA3229020A1 (en) | 2023-03-23 |
Family
ID=83691543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3229020A Pending CA3229020A1 (en) | 2021-09-14 | 2022-09-13 | Treatment of cardiovascular disease |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250283076A1 (https=) |
| EP (1) | EP4402263A2 (https=) |
| JP (1) | JP2024531728A (https=) |
| CA (1) | CA3229020A1 (https=) |
| WO (1) | WO2023041508A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| WO2024189348A1 (en) * | 2023-03-14 | 2024-09-19 | Argonaute RNA Limited | Conjugate comprising a double stranded rna molecule linked to a single stranded dna molecule |
| WO2024228030A2 (en) * | 2023-05-04 | 2024-11-07 | Argonaute RNA Limited | Dual silencing |
| EP4722365A1 (en) * | 2023-05-26 | 2026-04-08 | Visirna Therapeutics (Suzhou) Co., Ltd. | Double-stranded nucleotide compound for metabolic diseases and use thereof |
| CN119464281A (zh) * | 2023-08-09 | 2025-02-18 | 北京福元医药股份有限公司 | 抑制DGAT2基因表达的siRNA、siRNA缀合物或其前药和药物组合物及用途 |
| WO2025040139A1 (zh) * | 2023-08-23 | 2025-02-27 | 云合智药（苏州）生物科技有限公司 | 用于抑制二酰甘油-O-酰基转移酶2表达的RNAi剂及其应用 |
| TW202540420A (zh) * | 2023-11-15 | 2025-10-16 | 大陸商北京加科瑞康醫藥科技有限公司 | 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02008616A (es) | 2000-03-03 | 2003-02-24 | Smithkline Beecham Biolog | Vacuna para el tratamiento de la arterosclerosis. |
| GB0121171D0 (en) | 2001-08-31 | 2001-10-24 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0305794D0 (en) | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Vaccine |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| WO2005044981A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| EP1891216B1 (en) * | 2005-05-25 | 2012-02-22 | The University Of York | Hybrid interfering rna |
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| CA2658183A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| WO2010141511A2 (en) * | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
| WO2012058693A2 (en) * | 2010-10-29 | 2012-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of pcsk9 genes |
| IL292159B1 (en) * | 2012-12-05 | 2026-04-01 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA compositions and methods of using them |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| EP3011026B1 (en) | 2013-06-21 | 2019-12-18 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile |
| JOP20160211B1 (ar) | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| KR102502031B1 (ko) | 2016-11-16 | 2023-02-20 | 퍼듀 리서치 파운데이션 | 체중 및 대사 증후군을 조절하기 위한 조성물 및 방법 |
| HRP20230127T1 (hr) | 2017-11-13 | 2023-03-31 | Silence Therapeutics Gmbh | Nukleinske kiseline za inhibiranje ekspresije lpa u stanici |
| PH12021550801B1 (en) * | 2018-11-13 | 2024-04-26 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
| WO2021001646A2 (en) * | 2019-07-02 | 2021-01-07 | Argonaute RNA Limited | Apolipoprotein b antagonist |
| MX2022007005A (es) * | 2019-12-09 | 2022-08-25 | Amgen Inc | Construcciones de iarn y metodos para inhibir la expresion de lpa. |
| CN115066498A (zh) * | 2020-03-16 | 2022-09-16 | 阿尔戈诺特Rna有限公司 | Pcsk9的拮抗剂 |
-
2022
- 2022-09-13 WO PCT/EP2022/075355 patent/WO2023041508A2/en not_active Ceased
- 2022-09-13 CA CA3229020A patent/CA3229020A1/en active Pending
- 2022-09-13 EP EP22789482.1A patent/EP4402263A2/en active Pending
- 2022-09-13 JP JP2024516476A patent/JP2024531728A/ja active Pending
- 2022-09-13 US US18/691,775 patent/US20250283076A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024531728A (ja) | 2024-08-29 |
| WO2023041508A2 (en) | 2023-03-23 |
| WO2023041508A3 (en) | 2023-06-08 |
| EP4402263A2 (en) | 2024-07-24 |
| US20250283076A1 (en) | 2025-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3229020A1 (en) | Treatment of cardiovascular disease | |
| TWI908388B (zh) | 靶向調控PCSK9基因表達的siRNA及其應用 | |
| CN109957565B (zh) | 一种修饰的siRNA分子及其应用 | |
| EP3679138B1 (en) | Hnf4a sarna compositions and methods of use | |
| CN116490195A (zh) | 用于抑制脂蛋白(a)的RNA组合物和方法 | |
| EA015676B1 (ru) | Композиции и способы ингибирования экспрессии гена pcsk9 | |
| US20250304966A1 (en) | Treatment of cardiovascular disease | |
| CN115176011A (zh) | 用于抑制pcsk9的组合物和方法 | |
| KR102759742B1 (ko) | 막관통 세린 프로테아제 6(tmprss6) 발현을 억제하기 위한 조성물 및 방법 | |
| Gaddam et al. | γ peptide nucleic acid-based miR-122 inhibition rescues vascular endothelial dysfunction in mice fed a high-fat diet | |
| AU2025237953A1 (en) | siRNA for targeted inhibition of AGT gene expression and use thereof in treating hypertension | |
| JP5406024B2 (ja) | Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法 | |
| CN120505318B (zh) | LSR、LncRNA-LSR-AS1或靶向siRNA在预防和/或治疗高脂血症或其相关疾病中的应用 | |
| CN118103508A (zh) | 心血管疾病的治疗 | |
| WO2025082058A9 (zh) | 一种抑制LPA基因表达的dsRNA及其用途 | |
| WO2024228030A2 (en) | Dual silencing | |
| GB2618915A (en) | Treatment of cardiovascular disease | |
| AU2024290689A1 (en) | Dsrna molecule for inhibiting lp(a) gene expression and use thereof | |
| GB2635479A (en) | Dual silencing | |
| EP4680740A1 (en) | Conjugate comprising a double stranded rna molecule linked to a single stranded dna molecule | |
| CN121127587A (zh) | 用于抑制LPA表达的RNAi剂及其应用 | |
| WO2024182580A3 (en) | Rnai agents for inhibiting expression of pcsk9, pharmaceutical compositions thereof, and methods of use | |
| GB2629617A (en) | Dual silencing | |
| WO2026047010A1 (en) | Atg7 inhibitors for treatment of obesity and type 2 diabetes | |
| IE20060253A1 (en) | Methods for modulating the levels and effects of thyrotropin-releasing hormone(trh)and trh-related peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240905 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250904 |